Payment overview · 2025
General Payments
$1,359.26
39 reported records · 14 companies
Healthcare provider profile · identity verified
Neng Lee, NURSE PRACTITIONER
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · FRESNO, CA · NPI 1972511970
Verified facts
What the public records show
CMS Open Payments records show Neng Lee, NURSE PRACTITIONER received $1,359.26 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 357 claims for Synjardy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $387.38 | 28.5% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $208.89 | 15.4% | 8 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $132.68 | 9.8% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $125.00 | 9.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $124.99 | 9.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $102.19 | 7.5% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $65.61 | 4.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.05 | 3.4% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $42.50 | 3.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.81 | 2.1% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $27.73 | 2.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.38 | 2.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.24 | 1.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.81 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,316.76 | 38 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $362.86 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $208.89 | 8 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $102.19 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.05 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.05 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $43.68 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $42.50 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $28.81 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $27.73 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.24 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 228 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 132 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
153 | 117 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | 18 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
132 | 51 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
228 | 62 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
357 | 75 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
44 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
31 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
228 | 62 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
160 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 829 | 283 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 558 | 169 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 452 | 105 |
| Allopurinol | Allopurinol | 420 | 154 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 404 | 144 |
| Pantoprazole Sodium | Pantoprazole Sodium | 394 | 150 |
| Gabapentin | Gabapentin | 383 | 156 |
| Synjardy | Empagliflozin/Metformin Hcl | 357 | 75 |
| Azelastine Hcl | Azelastine Hcl | 343 | 94 |
| Losartan Potassium | Losartan Potassium | 286 | 99 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 281 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 240 | 80 |
| Jardiance | Empagliflozin | 228 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 227 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 204 | 71 |
| Metformin Hcl | Metformin Hcl | 187 | 73 |
| Omeprazole | Omeprazole | 183 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 72 |
| Trulicity | Dulaglutide | 160 | 36 |
| Benazepril Hcl | Benazepril Hcl | 159 | 51 |
| Prolia | Denosumab | 153 | 117 |
| Montelukast Sodium | Montelukast Sodium | 145 | 54 |
| Megestrol Acetate | Megestrol Acetate | 143 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 142 | 65 |
| Lisinopril | Lisinopril | 141 | 44 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 140 | 49 |
| Azithromycin | Azithromycin | 136 | 112 |
| Kerendia | Finerenone | 132 | 51 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 130 | 39 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 129 | 46 |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 125 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 124 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 45 |
| Lovastatin | Lovastatin | 107 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 100 | 31 |
| Famotidine | Famotidine | 99 | 32 |
| Ventolin Hfa | Albuterol Sulfate | 98 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 95 | 39 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 93 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 93 | 36 |
| Clonidine | Clonidine | 89 | 36 |
| Vascepa | Icosapent Ethyl | 84 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 83 | 29 |
| Rizatriptan | Rizatriptan Benzoate | 79 | 22 |
| Januvia | Sitagliptin Phosphate | 78 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 19 |
| Alendronate Sodium | Alendronate Sodium | 77 | 21 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 74 | 34 |
| Aripiprazole | Aripiprazole | 70 | 24 |
| Sertraline Hcl | Sertraline Hcl | 70 | 22 |
| Simvastatin | Simvastatin | 70 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 24 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 66 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 66 | 58 |
| Meclizine Hcl | Meclizine Hcl | 64 | 25 |
| Carvedilol | Carvedilol | 63 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 15 |
| Furosemide | Furosemide | 61 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 61 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 24 |
| Prednisone | Prednisone | 60 | 42 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 48 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 16 |
| Baclofen | Baclofen | 56 | 27 |
| Potassium Chloride | Potassium Chloride | 55 | 21 |
| Tramadol Hcl | Tramadol Hcl | 54 | 11 |
| Nifedipine Er | Nifedipine | 53 | 16 |
| Donepezil Hcl | Donepezil Hcl | 52 | 16 |
| Sucralfate | Sucralfate | 52 | 18 |
| Levofloxacin | Levofloxacin | 51 | 36 |
| Olanzapine | Olanzapine | 50 | 17 |
| Breyna | Budesonide/Formoterol Fumarate | 49 | 17 |
| Fluconazole | Fluconazole | 48 | 30 |
| Novolog Flexpen | Insulin Aspart | 48 | 18 |
| Humalog Kwikpen U-100 | Insulin Lispro | 47 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | 16 |
| Glipizide | Glipizide | 44 | 17 |
| Vemlidy | Tenofovir Alafenamide | 44 | 14 |
| Bumetanide | Bumetanide | 43 | 16 |
| Glimepiride | Glimepiride | 43 | 14 |
| Meloxicam | Meloxicam | 43 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | 13 |
| Ozempic | Semaglutide | 40 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 40 | 12 |
| Temazepam | Temazepam | 40 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 39 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 29 |
| Levetiracetam | Levetiracetam | 38 | 11 |
| Lorazepam | Lorazepam | 37 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 29 |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | 13 |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 36 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 13 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 35 | 18 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 34 | 14 |
| Droplet Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | 11 |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 31 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 31 | 28 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | 18 |
| Ezetimibe | Ezetimibe | 28 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | 11 |
| Ramipril | Ramipril | 28 | 11 |
| Valacyclovir | Valacyclovir Hcl | 28 | 16 |
| Amoxicillin | Amoxicillin | 27 | 24 |
| Colchicine | Colchicine | 27 | 14 |
| Nystatin | Nystatin | 27 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 16 |
| Procto-Med Hc | Hydrocortisone | 27 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 26 | 13 |
| Eliquis | Apixaban | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 25 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 25 | 21 |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Dutasteride | Dutasteride | 24 | 11 |
| Pregabalin | Pregabalin | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 13 |
| Ofloxacin | Ofloxacin | 23 | 16 |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | 19 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 20 |
| Mupirocin | Mupirocin | 20 | 18 |
| Alprazolam | Alprazolam | 19 | suppressed |
| Fluocinonide | Fluocinonide | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 18 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 18 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 17 | 17 |
| Spironolactone | Spironolactone | 17 | suppressed |
| Typhim Vi | Typhoid Vi Polysacch Vaccine | 16 | 16 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 15 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Desloratadine | Desloratadine | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Ultra Flo Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Entecavir | Entecavir | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,359.26 · 39 records | AstraZeneca Pharmaceuticals LP | AFREZZA, AIRSUPRA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, KEVEYIS, Kerendia, Korlym, OTEZLA, Omnipod, REPATHA, TEZSPIRE, TRELEGY ELLIPTA, VRAYLAR, Wegovy, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error